(Q43609601)

25 November 2017

title

Swiss analysis of multiple sclerosis: a multicenter, non-interventional, retrospective cohort study of disease-modifying therapies (English)

1 reference

25 November 2017

0 references

3

Michael Linnebank

1 reference

25 November 2017

Claudio Gobbi

1

1 reference

25 November 2017

Chiara Zecca

2

1 reference

25 November 2017

Stefanie Müller

4

1 reference

25 November 2017

Xiaojun You

5

1 reference

25 November 2017

Rosetta Meier

6

1 reference

25 November 2017

Emmanuela Borter

7

1 reference

25 November 2017

Martin Traber

8

1 reference

25 November 2017

publication date

14 May 2013

1 reference

25 November 2017

1 reference

25 November 2017

volume

70

1 reference

25 November 2017

issue

1-2

1 reference

25 November 2017

page(s)

35-41

1 reference

Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG)

25 November 2017

cites work

1 reference

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group

21 January 2018

1 reference

Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. II. MRI analysis results of a multicenter, randomized, double-blind, placebo-controlled trial. UBC MS/MRI Study Group and the IFNB Multiple Sclerosis Study Group

21 January 2018

1 reference

250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study

21 January 2018

1 reference

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

21 January 2018

1 reference

Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN).

21 January 2018

1 reference

A post-marketing study on interferon beta 1b and 1a treatment in relapsing-remitting multiple sclerosis: different response in drop-outs and treated patients

21 January 2018

1 reference

Interferon beta in relapsing-remitting multiple sclerosis: an independent postmarketing study in southern Italy

21 January 2018

1 reference

Effects of interferon beta-1a and -1b over time: 6-year results of an observational head-to-head study.

21 January 2018

1 reference

Quality Assessment in Multiple Sclerosis Therapy (QUASIMS): a comparison of interferon beta therapies for relapsing-remitting multiple sclerosis

21 January 2018

1 reference

Twenty-four-month comparison of immunomodulatory treatments - a retrospective open label study in 308 RRMS patients treated with beta interferons or glatiramer acetate (Copaxone).

21 January 2018

1 reference

Immunomodulatory treatment of multiple sclerosis in denmark: a prospective nationwide survey

21 January 2018

1 reference

Diagnostic criteria for multiple sclerosis: 2005 revisions to the “McDonald Criteria”

21 January 2018

1 reference

Current disease-modifying treatment of multiple sclerosis

21 January 2018

1 reference

Randomized controlled trials to assess therapies for multiple sclerosis

21 January 2018

1 reference

A comparison of observational studies and randomized, controlled trials

21 January 2018

1 reference

European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis

21 January 2018

1 reference

Interferon beta in relapsing–remitting multiple sclerosis

21 January 2018

1 reference

Randomised double-blind placebo-controlled study of interferon β-1a in relapsing/remitting multiple sclerosis

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000346761

1 reference

25 November 2017

1 reference